ORMP : Summary for Oramed Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.09+0.08 (+1.33%)
At close: 4:00PM EDT
People also watch
OHRPVBLTCNATCANFONTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close6.01
Open6.01
Bid5.75 x 1000
Ask6.20 x 100
Day's Range5.97 - 6.09
52 Week Range5.70 - 10.51
Volume32,501
Avg. Volume21,214
Market Cap80.9M
Beta1.05
PE Ratio (TTM)-7.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
    PR Newswire6 days ago

    Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

    Dr. Kidron will address a novel platform for preserved bioavailability and effective delivery of protein and peptide therapeutics. Data and other results demonstrating applicability of this platform toward delivery of insulin and GLP-1 to manage diabetes, as assessed in animal models, healthy volunteers and in both type 1 and type 2 diabetes patients, will be presented. In addition, the physiological benefits of oral versus subcutaneous insulin delivery will be discussed.

  • Oramed Appoints Dr. Ronald Law as Chief Strategy Officer
    PR Newswire7 days ago

    Oramed Appoints Dr. Ronald Law as Chief Strategy Officer

    JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer. "We are very pleased to welcome Dr. Law to Oramed as we head towards a Phase III trial for our oral insulin capsule, ORMD-0801 and position Oramed for eventual commercialization of oral insulin.  With over 25 years of academic and industry experience in developing new approaches to treat diabetes and its complications, Dr. Law will play a vital role in helping to guide Oramed through our upcoming milestone events," stated Oramed CEO Nadav Kidron.

  • GuruFocus.com2 months ago

    While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever

    Recent lawsuits have accelerated smaller players in the diabetes space